Downloaded from dmd.aspetjournals.org at ASPET Journals on March 30, 2015

Short Communication

Biotransformation of Prasugrel, a Novel Thienopyridine Antiplatelet Agent, to the Pharmacologically Active Metabolite

Received January 6, 2010; accepted February 26, 2010

ABSTRACT:

Prasugrel, a novel thienopyridine antiplatelet agent, undergoes rapid hydrolysis in vivo to a thiolactone, R-95913, which is further converted to its thiol-containing, pharmacologically active metabolite, R-138727, by oxidation via cytochromes P450 (P450). We trapped a sulfenic acid metabolite as a mixed disulfide with 2-nitro-5-thiobenzoic acid in an incubation mixture containing the thiolactone R-95913, expressed CYP3A4, and NADPH. Further experiments investigated one possible mechanism for the conversion of the sulfenic acid to the active thiol metabolite in vitro. A mixed

Prasugrel [Effient (Eli Lilly and Company, Indianapolis, IN) in the United States and Efient (Eli Lilly and Company) in the European Union], clopidogrel [Plavix (Sanofi-Aventis, Paris, France)/Iscover (Bristol-Myers Squibb, New York, NY)], and ticlopidine (Ticlid; Sanofi-Aventis) are thienopyridine antiplatelet agents. Prasugrel has been shown to reduce the rate of thrombotic cardiovascular events and stent thrombosis in patients with acute coronary syndrome that are undergoing percutaneous coronary intervention (Wiviott et al., 2007) (Effient package insert). The thienopyridines are prodrugs that are converted in vivo to their pharmacologically active metabolites that possess a thiol group via a corresponding thiolactone metabolite (Farid et al., 2010). However, with the exception of an oxidation step catalyzed by cytochrome P450 (Savi et al., 1994; Rehmel et al., 2006), the mechanism for the active metabolite formation from thienopyridines remained unknown until recently reported for ticlopidine and clopidogrel (Dansette et al., 2009). In the case of prasugrel, the active metabolite R-138727 was not detected when the thiolactone metabolite R-95913 was incubated with liver homogenates or microsomes in the absence of cofactors, but it was detected when NADPH and a reducing agent such as glutathione were added to the system (Kazui et al., 2000). A sulfenic acid, which is a likely intermediate for the activation of prasugrel, reacts readily with a thiol compound, typically glutathione in vivo, to yield a disulfide metabolite (Decker et al., 1991; Kassahun et al., 2001; Reddy et al., 2005; Dansette et al., 2009). The formed disulfide can be further reduced to provide a thiolcontaining compound. The objective of this study is to investigate the

N.A.F. has retired from Eli Lilly and Company.

Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

doi:10.1124/dmd.110.032086.

disulfide form of R-138727 with glutathione was found to be a possible precursor of R-138727 in vitro when glutathione was present. The rate constant for the reduction of the glutathione conjugate of R-138727 to R-138727 was increased by addition of human liver cytosol to the human liver microsomes. Thus, one possible mechanism for the ultimate formation of R-138727 in vitro can be through formation of a sulfenic acid mediated by P450s followed possibly by a glutathione conjugation to a mixed disulfide and reduction of the disulfide to the active metabolite R-138727.

involvement of a sulfenic acid and a glutathione conjugate of R-138727 in the in vitro production of prasugrel's active metabolite (R-138727) from the thiolactone intermediate (R-95913) (Fig. 1).

Materials and Methods

Materials. R-138727 (prasugrel active metabolite), glutathione conjugate of R-138727, and R-95913 (prasugrel thiolactone metabolite) were synthesized by Ube Industries, Ltd. (Ube, Japan). 5,5'-Dithio-bis(2-nitrobenzoic acid) (DTNB) and tris(carboxyethyl)phosphine (TCEP), used as a reagent to reduce DTNB to 2-nitro-5-thiobenzoic acid (TNB), were purchased from Sigma-Aldrich (St. Louis, MO). Microsomes from insect cells that expressed CYP3A4 (cDNA-expressed CYP3A4) were purchased from Gentest Corporation (Woburn, MA). All other chemicals and reagents were commercially available and were of the highest grade. Water was purified by using a Milli-Q purification system (Millipore Corporation, Billerica, MA).

Preparation of TNB-R-138727 Disulfide. A mixed disulfide of R-138727 with TNB (TNB-R-138727 disulfide) was prepared by reacting R-138727 with equimolar DTNB in an aqueous solution (Fig. 2) because the synthesis using the chemically unstable sulfenic acid-derivative of R-138727 and TNB was difficult to perform. After dilution of the reaction mixture with acetonitrile and after centrifugation, a 20- μ l aliquot of the supernatant fraction was directly injected onto a YMC-Pack ODS-A (A-312) column (150 mm × 6.0 mm i.d., 5 µm; YMC Co., Ltd., Kyoto, Japan), maintained at ambient temperature. A high-performance liquid chromatography (HPLC) analysis was performed by using a low-pressure gradient elution system that consisted of an L-7100 Intelligent Pump, a D-7500 Chromato-Integrator, and an L-7400S UV Detector (Hitachi, Ltd., Tokyo, Japan). The mobile phase, 30% (v/v) acetonitrile in water that contained 0.01% (v/v) trifluoroacetic acid, was used at a flow rate of 1.0 ml/min. Profiling of the reaction products was performed with UV absorption detection at 220 nm. Two peaks in the chromatogram, which corresponded to the two diastereoisomers of TNB-R-138727 disulfide [retention times 19.18 (Peak A) and 21.57 (Peak B) min], were collected separately and lyophilized for structure elucidation by liquid chromatog-

ABBREVIATIONS: prasugrel, 2-acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine; DTNB, 5,5'-dithiobis(2-nitrobenzoic acid); TCEP, tris(carboxyethyl)phosphine; TNB, 2-nitro-5-thiobenzoic acid; HPLC, high-performance liquid chromatography; LC-MS/MS, liquid chromatography with tandem mass spectrometry; LC-MS, liquid chromatography-mass spectrometry; ESI, electrospray ionization; MS, mass spectrometry; MPBr, *m*-methoxyphenacybromide; MS/MS, tandem mass spectrometry.



R-138727 (Active metabolite)

FIG. 1. Proposed metabolic pathway from the thiolactone of prasugrel to the pharmacologically active metabolite via a sulfenic acid intermediate. TNB was used to trap a sulfenic acid intermediate forming TNB-R-138727 disulfide. GSSG, oxidized form of glutathione.

raphy with tandem mass spectrometry (LC-MS/MS) and NMR analysis, as described below.

Identification of TNB-R-138727 Disulfide. Electrospray ionization (ESI) analysis was performed by using a Q-TOF hybrid-type MS/MS spectrometer (Micromass UK, Ltd., Manchester, UK). A liquid chromatography-mass spectrometry (LC-MS) analysis in the ESI mode was performed by using a low-pressure gradient system that consisted of an L-6000, an L-6300 Intelligent Pump, a D-2500 Chromato-Integrator, and an L-4000 UV-Detector (Hitachi, Ltd.) equipped with a YMC Pack ODS-A column (50 mm × 1.5 mm i.d., 5 μ m). The other conditions for HPLC were the same as those described above. The flow rate was set at 1 ml/min, and after passage through the column, the eluent was introduced to the ESI source at a flow rate of approximately 100 μ l/min. The acceleration voltage of 3.3 kV and the cone voltage of 45 to 50 V were used in this ionization mode. The source block was maintained at 120°C. The desolvation gas was heated to 300°C. Xenon was used as the collision gas, and the laboratory frame collision energy was 20 eV when acquiring the product ion spectra.

After purification of Peaks A and B by HPLC, NMR analysis was performed by using a Varian (INOVA-500; Varian, Inc., Palo Alto, CA) 500 MHz spectrometer, and results were reported as δ in parts per million relative to Me₄Si as the internal standard. Abbreviations of the ¹H NMR peak splitting patterns are as follows: bs, broad singlet; s, singlet; and m, multiplet.

Metabolism of R-95913 by cDNA-Expressed CYP3A4 Supplemented with NADPH in the Presence of TNB or DTNB. Duplicate mixtures (total volume of 390 μ l each) containing potassium phosphate buffer (final concentration: 11.25 mM, pH 7.4), NADP (final concentration: 2.5 mM), D-glucose 6-phosphate (final concentration: 25 mM), glucose-6-phosphate dehydrogenase (final concentration: 0.5 units/ml), magnesium chloride (final concentration: 10 mM), and cDNA-expressed CYP3A4 (final concentration: 800 pmol/ ml) were preincubated at 37°C for 5 min in the presence of 1 mM TNB or DTNB as final concentration. TNB was prepared immediately before use by mixing equimolar DTNB with TCEP, dissolved in buffer (Han and Han, 1994). Then, 10 μ l of R-95913 (final concentration: 250 μ M) was added to the mixture, which was further incubated at 37°C for 0, 15, 30, and 60 min. At each time point, 80 μ l of the incubation mixture was collected, added to 160 μ l of acetonitrile to stop the reaction, and centrifuged (15,000g, 3 min, 4°C). For determination of R-95913, the supernatant samples were diluted with the supernatant fraction obtained by adding acetonitrile to cDNA-expressed CYP3A4 without any other components and after centrifugation. A 10 μ l-aliquot of each sample was subjected to a LC-MS analysis as described in the following section.

Quantification of R-95913, R-138727, and TNB-R-138727 Disulfide by LC-MS. Quantification of R-95913, R-138727, and TNB-R-138727 in the incubation mixture of R-95913 was carried out on an Alliance HPLC system that consisted of a 2795 Separations Module (Waters Corporation, Milford, MA) coupled to a ZQ-2000 (Waters Corporation) with the ESI source in positive ion mode. Each sample (10 μ l) was injected onto an XTerra MS C18 column (50 mm × 2.1 mm i.d., 3.5 μ m; Waters Corporation), which was maintained at 40°C. A two-component mobile phase (pumped at 0.5 ml/min) contained solvent A, which is a mixture of formic acid, 5 mM ammonium acetate, and acetonitrile (0.2/95/5, v/v/v), and solvent B, which is a mixture of formic acid, 5 mM ammonium acetate, and acetonitrile (0.2/5/95, v/v/v). The mobile phase initially consisted of 100% solvent A for 0 to 1 min, then solvent B was increased from 50 to 100% linearly from 1 to 3.75 min, and was maintained at 100% B from 3.75 to 4.5 min, before recycling back to the initial condition.

The operating parameters of the mass spectrometry (MS) detector were set as follows: capillary voltage, 3.5 kV; ion source temperature, 100°C; capillary temperature, 350°C; cone gas (N₂) flow and desolvation gas (N₂) flow, 50 l/h and 400 l/h, respectively; multiplier voltage, 650 V. Detection was performed in the single ion monitoring mode. The cone voltages were 33, 33, and 27 V with selected reaction monitoring of m/z 332, 350, and 547 for R-95913,



FIG. 2. Thiol-exchange reaction of R-138727 with DTNB forming TNB-R-138727 disulfide.

R-138727, and TNB-R-138727 disulfide, respectively. Phenacetin (Sigma-Aldrich) was used as the internal standard. The concentrations of each analyte in the samples were calculated by using the computer software MassLynx (version 3.5; Micromass UK Ltd.) and are expressed to three significant figures.

Standard stock solution that contained 1 mM TNB-R-138727 disulfide in 50% ethanol solution was prepared by adding a solution of DTNB in potassium phosphate buffer to that of R-138727 in ethanol at a final concentration of 1 mM. This standard stock solution was diluted 2-fold sequentially with acetonitrile to prepare standard solutions of a TNB-R-138727 disulfide at concentrations from 15.6 to 1000 nM. In the same manner as described above, standard solutions of R-95913 or R-138727 were prepared by diluting the standard stock solution that contained 1 mM R-95913 or 1 mM R-138727 sequentially 2-fold with acetonitrile. The calibration curves were constructed by plotting the peak area ratios of the standard compound to the internal standard versus the nominal concentrations.

Formation of the Glutathione Conjugate and R-138727 by cDNA-Expressed CYP3A4. Duplicate mixtures (total volume of 990 µl each) that contained potassium phosphate buffer (final concentration: 29-34 mM, pH 7.4), NADP (final concentration: 2.5 mM), D-glucose 6-phosphate (final concentration: 25 mM), glucose-6-phosphate dehydrogenase (final concentration: 0.5 units/ml), magnesium chloride (final concentration: 10 mM), and cDNAexpressed CYP3A4 (final concentration: 108 pmol/ml) with or without glutathione (final concentration: 5 mM) were preincubated at 37°C for 5 min. Then, 10 µl of R-95913, glutathione conjugate of R-138727, or R-138727 (final concentration: 1, 0.4, or 1 μ M, respectively) were added to the mixture, which was further incubated at 37°C for 5, 15, 30, 45, and 60 min. At each time point, 160 µl of the incubation mixture was collected, added to the solution containing 320 µl of methanol, 3.2 µl of 500 mM m-methoxyphenacybromide (MPBr solution in acetonitrile), and 160 µl of the internal standard solution (100 ng/ml R-135766) to terminate the reaction. The mixture was stored at room temperature for 10 min and centrifuged (15,000g, 3 min, 4°C). A 10 µl-aliquot of the supernatant fraction was subjected to the LC-MS/MS system as described below.

Formation of the Glutathione Conjugate Metabolite and R-138727 from R-95913 in Human Liver Microsomes and Cytosol. Triplicate mixtures (total volume of 990 µl each) contained 36-39 mM potassium phosphate buffer (pH 7.4), an NADPH-generating system (NADP+ 1.55 mM), 3.3 mM glucose 6-phosphate, 0.4 units/ml glucose-6-phosphate dehydrogenase, 3.3 mM MgCl₂, 5 mM glutathione, and 1 mg/ml human liver microsome with or without human liver cytosol (1 mg/ml). Each mixture was preincubated at 37°C for 5 min, and 10 µl of R-95913 (10 µM as a final concentration) was added to each respective mixture, which was incubated at 37°C for 1, 2, 5, 10, 15, and 30 min. At each time point, 100 μ l of the incubation mixture was collected and mixed with a double amount of 5 mM MPBr acetonitrile solution and an equivalent amount of the internal standard solution to stop the reaction and left for 10 min at room temperature to derivatize the thiol moiety of R-138727. After derivatization, the mixture was centrifuged (15,000g, 3 min, 4°C). A 10 µl-aliquot of the supernatant fraction was subjected to LC-MS/MS analysis.

Calculation of Rate Constants for Formation of the Glutathione Conjugate Metabolite and R-138727. As one possible pathway, the kinetic model for the formation of the glutathione conjugate of R-138727 and R-138727 from R-95913 in a closed incubation system is shown in Fig. 3. The corresponding differential equations for this model are as follows:



FIG. 3. Schematic diagram of the model for the formation of the glutathione conjugate of R-138727 and R-138727 from R-95913 in a closed incubation system. k1, rate constant of the formation of the glutathione conjugate of R-138727 from R-95913; k2, rate constant of the formation of R-138727 from the glutathione conjugate of R-138727; k3, rate constant of the formation of the glutathione conjugate of R-138727 from R-138727; k4, rate constant of conversion of R-95913 to the metabolites other than the glutathione conjugate of R-138727 and R-138727.

$$\frac{dZ(1)}{dt} = -(k1 + k4) \times Z(1)$$
(1)

$$\frac{dZ(2)}{dt} = k1 \times Z(1) - k2 \times Z(2) + k3 \times Z(3)$$
(2)

$$\frac{\mathrm{d}Z(3)}{\mathrm{d}t} = \mathrm{k}2 \times \mathrm{Z}(2) - \mathrm{k}3 \times \mathrm{Z}(3) \tag{3}$$

where Z(1) (eq. 1), Z(2) (eq. 2), and Z(3) (eq. 3) represent the concentrations of R-95913, the glutathione conjugate of R-138727, and R-138727, respectively, and k1, k2, k3, and k4 represent the rate constants of the formation of the glutathione conjugate of R-138727 from R-95913 (reflecting the rate-limiting, likely the oxidation, step in two consecutive steps), the formation of R-138727 from the glutathione conjugate of R-138727, and conversion of R-95913 to metabolites other than the glutathione conjugate of R-138727, and R-138727 and R-138727, respectively. The concentrations of the glutathione conjugate of R-138727 and R-138727 and R-138727 and R-138727 and R-138727 metabolites other than the glutathione conjugate of R-138727 metabolites of the glutathione conjugate of R-138727 metabolites other than the glutathione conjugate of R-138727, respectively. The concentrations of the glutathione conjugate of R-138727 metabolites other (version 4.0.1; Pharsight, Mountain View, CA).

Quantification of R-95913, R-138727, and Glutathione Conjugate by LC-MS/MS. The assays were performed based on the methods described in the preceding section and a previous report by Farid et al., 2007b. Quantification of R-95913, MPBr-derivatized R-138727, and glutathione conjugate was carried out with an Alliance HPLC system, which consisted of 2690 Separations Module (Waters Corporation) coupled to a Quattro LC-MS/MS system (Waters Corporation) with the ESI source in positive ion mode. The mobile phase that contained methanol, purified water, and trifluoroacetic acid (570/430/0.5, v/v/v) was applied on an Inertsil ODS-3 column (150 mm \times 2.1 mm i.d., 5 μ m; GL Sciences Inc., Tokyo, Japan).

The concentrations of each analyte in the samples were calculated by using MassLynx software (version 4.0; Waters Corporation). The standard stock solution was diluted 5-fold sequentially with acetonitrile to prepare the standard solutions at concentrations from 1.6 to 1000 nM. The standard curves were generated by using each analyte's peak area ratio equal to that of the internal standard versus the nominal concentration of the analytes.

Results

TNB-R-138727 Disulfide. The thiol-exchange reaction of R-138727 with DTNB (Fig. 2) and trapping the sulfenic acid intermediate of R-138727 with TNB (Fig. 1) generate a mixed disulfide between TNB and R-138727 (TNB-R-138727 disulfide). We synthesized TNB-R-138727 disulfide as the reference standard for analysis by mixing DTNB and R-138727 (Fig. 2) because TNB and sulfenic acid are unstable and unavailable. Major reaction products appeared as two chromatographic peaks, Peaks A and B. The MS and tandem mass spectrometry (MS/MS) spectra of Peaks A and B had identical fragmentation patterns as well as exact mass and relative intensity of the fragment ions, which demonstrated that Peaks A and B are diastereoisomers. The presence of the diastereoisomers is consistent with the chemical structure of TNB-R-138727 disulfide, which possesses two asymmetric carbons adjacent to the sulfur and nitrogen atoms. The $(M+H)^+$ ions observed in MS spectra of Peaks A and B were detected with m/z 547. The MS/MS spectrum of the $(M+H)^+$ ion with m/z 547 gave a series of fragment ions with m/z 206, 248, and 317, and the proposed assignments of the fragment ions are shown in Fig. 4. The ion with m/z 317 was considered to be a fragment ion of $(M+H)^+$ produced by the elimination of the disulfanyl nitrobenzoic acid moiety as shown in proposed fragmentation in Fig. 4.

We determined the NMR spectra of Peaks A and B, which were mixed due to rapid epimerization to each other. ¹H NMR (pyridine- d_5) of the compounds were as follows: 0.82 ppm (2H, *m*), 1.09 ppm (2H, *m*), 2.07 ppm (1H, *m*), 2.38 ppm (2H, *m*), 2.81 ppm (2H, *m*), 3.36 ppm (2H, *m*), 4.96 and 4.98 ppm (total 1H, each *s*), 6.00 ppm (1H, *bs*), 6.26



FIG. 4. MS/MS spectra of Peak A (a) and Peak B (b) and proposed fragmentation in positive ion LC-ESI/MS.

and 6.32 ppm (total 1H, each s), 7.26 ppm (2H, m), 7.37 ppm (1H, m), 7.65 ppm (1H, m), 7.93 ppm (2H, m), 8.37 ppm (1H, s), clearly demonstrating that Peaks A and B are the mixed disulfide of R-138727 with TNB (Fig. 5).

Metabolism of R-95913 by cDNA-Expressed CYP3A4 Supplemented with NADPH in the Presence of DTNB or TNB. The thiolactone R-95913 was incubated with cDNA-expressed CYP3A4 supplemented with the NADPH-generating system. DTNB or TNB was added to the incubation mixture to trap the thiol-metabolite R-138727 (Fig. 2) or the sulfenic acid metabolite of R-138727 (Fig. 1), respectively, in the form of TNB-R-138727 disulfide. The concentrations of R-95913, R-138727, and TNB-R-138727 disulfide in the incubation mixture at various times as determined by LC/MS are shown in Fig. 6. The concentration of R-95913 gradually decreased along with increasing the incubation time in the presence of DTNB or TNB (Fig. 6, a or b, respectively). Upon incubating R-95913 in the presence of DTNB, the rate of the substrate decrease was slower than in the presence of TNB (1.7 \pm 1.4 and 5.6 \pm 1.8 μ M/min with DTNB and TNB, respectively, as mean \pm S.D. values), and this incubation produced neither TNB-R-138727 disulfide nor free R-138727, which indicates no production of the thiol-metabolite R-138727 (Fig. 6a). On the other hand, incubation in the presence of TNB led to a production of TNB-R-138727 disulfide, indicating the formation of the sulfenic acid intermediate (Fig. 6b). TCEP seemed to have no significant effect, except that a very low amount of R-138727 was detected (data not shown).

Formation of the Glutathione Conjugate of R-138727 and R-138727 by cDNA-Expressed CYP3A4. R-95913, glutathione conjugate of R-138727, or R-138727 was incubated with cDNA-expressed CYP3A4 in the presence of NADPH with or without gluta-

thione. Incubation of R-95913 with glutathione (Fig. 7a), but not without glutathione (Fig. 7b), showed immediate formation of the glutathione conjugate of R-138727, which was gradually decreased and was replaced by the formation of R-138727. Although the thiolactone decreased rapidly in the absence of glutathione (Fig. 7b), no active metabolite was detected. These data may indicate that other metabolic pathways may have been occurring simultaneously in the in vitro system. The glutathione conjugate of R-138727 when added to the incubation mixture rapidly decreased and converted to R-138727 in the presence of glutathione, but R-138727 formed very little in the absence of glutathione (Fig. 7c). R-138727 when added to the incubation mixture was minimally converted to the glutathione conjugate in the incubation mixture even in the presence of glutathione (Fig. 7d), and it remained stable in the presence/absence of glutathione (data not shown).

Effect of Human Liver Cytosol on the Formation of the Glutathione Conjugate of R-138727 and R-138727. R-95913 (10 μ M) was incubated in human liver microsomes (1 mg/ml protein) with or without human liver cytosol fraction (1 mg/ml protein) in the presence of 5 mM glutathione and an NADPH-generating system. The apparent formation of the glutathione conjugate of R-138727 was remarkably decreased when the human liver cytosol fraction was added to human liver microsomes with the formation rates of the glutathione conjugate of R-138727 and R-138727 of 54.2 ± 6.5 and 4.49 ± 1.77 pmol/ min/mg protein, respectively, in human liver microsomes and 9.28 ± 2.05 and 31.5 ± 7.1 pmol/min/mg protein, respectively, in a mixture of human liver microsomes and cytosols (expressed as mean ± S.D. values) (Fig. 8). The simultaneous fitting exhibited a good fit to the observed data. The rate constant of the formation of R-138727 from the glutathione conjugate of R-138727 (k2) was substantially in-



FIG. 5. ¹H NMR spectra of Peaks A and B obtained by NMR analysis.

creased by the addition of human liver cytosols (0.143 and 2.82 s⁻¹ without and with human liver cytosols, respectively) as shown in Fig. 8.

Discussion

We hypothesized that a sulfenic acid intermediate can be produced from the thiolactone intermediate of prasugrel, R-95913, and converted to a disulfide with glutathione in the process of producing the pharmacologically active metabolite R-138727 (Fig. 1). The basis for this hypothesis is that R-138727, the thiol metabolite, is not the immediate metabolite of R-95913 but the sulfenic acid formed is actually that of R-95913 (the reactant) and not of R-138727 (which is a product formed one or two steps later). In the present study, as a tool for trapping and detecting the sulfenic acid intermediate, we used



FIG. 6. Concentrations of R-95913 (•), R-138727 (◊), and TNB-R-138727 disulfide (▲) versus time during metabolism of R-95913 by cDNA-expressed CYP3A4 supplemented with an NADPH-generation system in the presence of DTNB (a) or TNB (b).

TNB, which forms a disulfide with the sulfenic acid groups (Lin et al., 1975; Boschi-Muller et al., 2000; Poole and Ellis, 2002; Poole et al., 2004). We also used DTNB, which forms a disulfide with thiol groups by a thiol exchange reaction (Riddles et al., 1979; Boschi-Muller et al., 2000), for R-138727 detection. A mixed disulfide of R-138727 with TNB (TNB-R-138727 disulfide) is a key substance in the present study because TNB-R-138727 disulfide could be produced either by a thiol exchange reaction between R-138727 and DTNB (Fig. 2) or by a coupling reaction between the sulfenic acid derivative of R-138727 and TNB (Fig. 1).

The sulfenic acid intermediate of R-138727 was detected as TNB-R-138727 disulfide after incubation of R-95913 with CYP3A4 and NADPH without glutathione (Fig. 6b), whereas R-138727 was not observed under this condition (Fig. 6a), indicating that the sulfenic acid of R-138727 is likely produced as an intermediate in the metabolism of R-95913 before the formation of R-138727. In addition, we showed the formation of a glutathione conjugate from R-95913 by CYP3A4 in the presence of glutathione (Fig. 7a) but not in the absence of glutathione (Fig. 7b). Because the sulfenic acid intermediate was formed even in the absence of glutathione (Fig. 6b), R-95913 is likely first oxidized to the sulfenic acid intermediate in a glutathione-independent manner and then possibly converted to a glutathione conjugate. Another glutathione molecule could then reduce the R-138727 glutathione conjugate to form R-138727. This concept is supported by the data showing that the glutathione conjugate is rapidly converted to R-138727 in the presence of glutathione (Fig. 7c), whereas R-138727 is minimally converted to its glutathione conjugate (Fig. 7d). Addition of cytosolic fraction to liver microsomes



resulted in much lower formation of the glutathione conjugate with increased formation of R-138727 (Fig. 8), indicating that the glutathione conjugate generated can be immediately reduced to R-138727 Very recently,

in the presence of cytosol. Reddy et al. (2005) determined that the formation of a thiol metabolite from sulfenic acid could proceed via a reduction or disproportionation step that would not be glutathione-dependent. This process is another possible metabolic pathway for prasugrel's active metabolite formation in vivo, and it would support the reported in vivo metabolic data in animals and humans (Farid et al., 2007a; Smith et al., 2007).

The conjugation with glutathione does not fully explain the observed stereoselectivity in prasugrel's active metabolite that was observed in vivo. In humans, greater concentrations of the R-configuration at the 4-position of R-138727 (Wickremsinhe et al., 2007) were observed in plasma. This in vivo stereoselectivity may be explained in part by the observed in vitro stereoselectivity in the P450-mediated oxidation of the thiolactone to R-138727 by cDNA-expressed P450 isoforms (Rehmel et al., 2006; Baker et al., 2008). In addition, stereoselective S-methylation of R-138727 was observed in vitro where the S-methylated metabolite of R-138727 was generated only R-138727 by cDNA-expressed CYP3A4 in the presence or absence of glutathione. A 1 μ M R-95913 with (a) or without (b) 5 mM glutathione, or 400 nM glutathione conjugate of R-138727 with/ without 5 mM glutathione (expressed as solid/dashed line, respectively) (c) or 1 μ M R-138727 with 5 mM glutathione (d) was incubated with cDNA-expressed CYP3A4 and NAPDH for 5, 15, 30, 45, and 60 min. The concentrations of R-95913 (\odot), R-138727 (\diamond), and glutathione conjugate of R-138727 (\times) were determined by LC-MS/MS. The graphs show the mean values of duplicated data.

FIG. 7. Formation of R-138727 and the glutathione conjugate of

from the S-configuration of R-138727 in human liver microsomes (Kazui et al., 2008).

Very recently, Dansette et al. (2009) proposed a scheme that included sulfenic acid and glutathione conjugation after the formation of thiolactones from clopidogrel and ticlopidine, which is similar to the one proposed here for prasugrel. Differences in the active metabolite formation from thienopyridines do exist, especially in the initial step to form the respective thiolactones. For both clopidogrel and ticlopidine, the first step in the formation of the thiolactone is an oxidative step in which reactive intermediates are likely to be formed, as evidenced by their mechanism-based inhibitory effects on the activities of CYP2B6 and CYP2C19 (Ha-Duong et al., 2001; Nishiya et al., 2009a,b). However, prasugrel is converted to the thiolactone by hydrolysis in the intestine during the absorption process through the action of carboxylesterases (Williams et al., 2008), and the key prasugrel metabolites are not mechanism-based inhibitors (Rehmel et al., 2006; Hagihara et al., 2008; Nishiya et al., 2009a,b). The active metabolite of clopidogrel is thought to be formed primarily in the liver (Savi et al., 1992; Farid et al., 2010), whereas the active metabolite of prasugrel is thought to be partly formed by intestinal CYP3A before the thiolactone reaches the liver (Farid et al., 2007, 2010).



FIG. 8. Formation of the glutathione conjugate of R-138727 and R-138727 from R-95913 in human liver microsomes and cytosols. R-95913 (10 μ M) was incubated in 1 mg/ml human liver microsomes (a) or 1 mg/ml human liver microsomes and cytosols (b) supplemented with 5 mM glutathione and an NADPH-generating system. The concentrations of R-138727 (\diamond) and glutathione conjugate of R-138727 (\times) were determined over time (mean + S.D., n =3). The solid lines represent the simultaneous fitting curves of the concentration-time profiles of R-138727 and the glutathione conjugate of R-138727. In conclusion, the results of the present in vitro study have provided insight into the bioactivation mechanisms of prasugrel, including a sulfenic acid intermediate and possibly a glutathione conjugate, although there are marked differences in thiolactone formation and site of active metabolite formation among thienopyridines.

Acknowledgments. We thank Drs. Takashi Izumi and Takahiro Murai (Daiichi Sankyo Co., Ltd.) and Drs. Mary Pat Knadler and Steven A. Wrighton (Eli Lilly and Company) for helpful comments and discussion on this study.

Drug Metabolism & Pharmacokinetics	Katsunobu Hagihara
Research Laboratories (K.H., M.K.,	Miho Kazui
A.K., H.I., M.I., O.O.) and Medicinal	Atsushi Kurihara
Chemistry Research Laboratories I	HARUO IWABUCHI
(H.K., N.T.), Daiichi Sankyo Co., Ltd.,	Minoru Ishikawa
Tokyo, Japan; Department of Drug	Hiroyuki Kobayashi
Disposition, Lilly Research	NAOKI TANAKA
Laboratories, Eli Lilly and Company,	Osamu Okazaki
Indianapolis, Indiana (N.A.F.); and	NAGY A. FARID
Yokohama College of Pharmacy,	Toshihiko Ikeda
Yokohama, Japan (T.I.)	

References

- Baker JAR, Oluyedun OA, Farid NA, Ring BJ, Wrighton SA, Kurihara A, and Guo Y (2008) Formation of the isomers of the active metabolite of prasugrel by allelic variants of the human cytochrome P450 isozymes. *Drug Metab Rev* **40** (Suppl 3):322.
- Boschi-Muller S, Azza S, Sanglier-Cianferani S, Talfournier F, Van Dorsselear A, and Branlant G (2000) A sulfenic acid enzyme intermediate is involved in the catalytic mechanism of peptide methionine sulfoxide reductase from Escherichia coli. J Biol Chem 275:35908–35913.
- Dansette PM, Libraire J, Bertho G, and Mansuy D (2009) Metabolic oxidative cleavage of thioesters: evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel. *Chem Res Toxicol* 22:369–373.
- Decker CJ, Cashman JR, Sugiyama K, Maltby D, and Correia MA (1991) Formation of glutathionyl-spironolactone disulfide by rat liver cytochromes P450 or hog liver flavincontaining monooxygenases: a functional probe of two-electron oxidations of the thiosteroid? *Chem Res Toxicol* 4:669–677.
- Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, and Goldberg MJ (2007a) The disposition of prasugrel, a novel thienopyridine, in humans. *Drug Metab Dispos* 35:1096– 1104.
- Farid NA, McIntosh M, Garofolo F, Wong E, Shwajch A, Kennedy M, Young M, Sarkar P, Kawabata K, Takahashi M, et al. (2007b) Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry. *Rapid Commun Mass Spectrom* 21:169–179.
- Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, and Salazar DE (2007) Cytochrome P4503A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. *Clin Pharmacol Ther* 81:735–741.
- Farid NA, Kurihara A, and Wrighton SA (2010) The metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 50:126–142.

Ha-Duong NT, Dijols S, Macherey AC, Dansette PM, and Mansuy D (2001) Inhibition by

ticlopidine and its derivatives of human liver cytochrome p450. Mechanism-based inactivation of CYP 2C19 by ticlopidine. *Adv Exp Med Biol* **500**:145–148.

- Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, and Ikeda T (2008) Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet 23:412–420.
- Han JC and Han GY (1994) A procedure for quantitative determination of tris(2carboxyethyl)phosphine, an odorless reducing agent more stable and effective than dithiothreitol. *Anal Biochem* **220**:5–10.
- Kassahun K, Pearson PG, Tang W, McIntosh I, Leung K, Elmore C, Dean D, Wang R, Doss G, and Baillie TA (2001) Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. *Chem Res Toxicol* 14:62–70.
- Kazui M, Hagihara K, Farid NA, and Kurihara A (2008) Stereoselectivity of thiol S-methyl transferase responsible for the methylation of the active metabolite of prasugrel. *Drug Metab Rev* **40** (Suppl 3):101.
- Kazui M, Ishizuka T, Yamamura N, Iwabuchi H, Kita J, Yoneda K, Kurihara A, Hirota T, and Ikeda T (2000) Mechanism for metabolic activation of CS-747, a new thienopyridine antiplatelet agent. *13th International Symposium on Microsomes and Drug Oxidations*; 2001 Jul 10–14; Stresa, Italy. Clinical Pharmacology and Therapeutics, Alexandria, VA.
- Lin WS, Armstrong DA, and Gaucher GM (1975) Formation and repair of papain sulfenic acid. Can J Biochem 53:298–307.
- Nishiya Y, Hagihara K, Kurihara A, Okudaira N, Farid NA, Okazaki O, and Ikeda T (2009a) Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel. *Xenobiotica* 39:836–843.
- Nishiya Y, Hagihara K, Ito T, Tajima M, Miura S, Kurihara A, Farid NA, and Ikeda T (2009b) Mechanism-based inhibition of human cytochrome P450 2B6 by ticlopidine, clopidogrel, and the thiolactone metabolite of prasugrel. *Drug Metab Dispos* 37:589–593.
- Poole LB and Ellis HR (2002) Identification of cysteine sulfenic acid in AhpC of alkyl hydroperoxide reductase. *Methods Enzymol* 348:122–136.
- Poole LB, Karplus PA, and Claiborne A (2004) Protein sulfenic acids in redox signaling. Annu Rev Pharmacol Toxicol 44:325–347.
- Riddles PW, Blakeley RL, and Zerner B (1979) Ellman's reagent: 5,5'-dithiobis(2-nitrobenzoic acid)–a reexamination. Anal Biochem 94:75–81.
- Reddy VB, Karanam BV, Gruber WL, Wallace MA, Vincent SH, Franklin RB, and Baillie TA (2005) Mechanistic studies on the metabolic scission of thiazolidinedione derivatives to acyclic thiols. *Chem Res Toxicol* 18:880–888.
- Rehmel JL, Eckstein JA, Farid NA, Heim JB, Kasper SC, Kurihara A, Wrighton SA, and Ring BJ (2006) Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. *Drug Metab Dispos* 34:600–607.
- Savi P, Herbert JM, Pflieger AM, Dol F, Delebassee D, Combalbert J, Defreyn G, and Maffrand JP (1992) Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. *Biochem Pharmacol* 44:527–532.
- Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y, and Herbert JM (1994) The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450–1A. *Thromb Haemost* 72:313–317.
- Smith RL, Gillespie TA, Rash TJ, Kurihara A, and Farid NA (2007) Disposition and metabolic fate of prasugrel in mice, rats, and dogs. *Xenobiotica* 37:884–901.
- Wickremsinhe ER, Tian Y, Ruterbories KJ, Verburg EM, Weerakkody GJ, Kurihara A, and Farid NA (2007) Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method. *Drug Metab Dispos* 35:917–921.
 Williams ET, Jones KO, Ponsler GD, Lowery SM, Perkins EJ, Wrighton SA, Ruterbories KJ,
- Williams ET, Jones KO, Ponsler GD, Lowery SM, Perkins EJ, Wrighton SA, Ruterbories KJ, Kazui M, and Farid NA (2008) The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. *Drug Metab Dispos* 36:1227–1232.
- Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, et al. (2007) Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357:2001–2015.

Address correspondence to: Katsunobu Hagihara, Drug Metabolism & Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-Ku, Tokyo, 140-8710, Japan. E-mail: hagihara.katsunobu.fc@daiichisankyo. co.jp